Company Highlights - Alnylam Pharmaceuticals had an active 2024, with a significant highlight being the positive results from the Phase III HELIOS-B study of Amvuttra (vutrisiran) in ATTR amyloidosis with cardiomyopathy (ATTR-CM) [1] Clinical Trial Results - The Phase III HELIOS-B study of Amvuttra (vutrisiran) showed very positive results in treating ATTR-CM, a key development for the company [1] Future Prospects - The potential impact of the HELIOS-B study results on the company's future remains to be seen, but it represents a significant milestone in its clinical pipeline [1]

Alnylam Pharmaceuticals (ALNY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Si ...

Alnylam Pharmaceuticals (ALNY) announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the label expansion of Amvuttra (vutrisiran) for review to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM). Amvuttra, an RNAi therapeutic, is ALNY’s lead drug, which is currently approved in the United States for treating adult patients with polyneuropathy of transthyretin-mediated (hATTR) amyloidosis. It is also marketed in the EU for treating hATTR amyloidosis in adult patients with ...

Alnylam Pharmaceuticals (ALNY) reported third-quarter 2024 adjusted loss of 50 cents per share, which matched the Zacks Consensus Estimate. The company had recorded earnings of $1.74 per share in the year-ago quarter. The adjusted figure excluded items like stock-based compensation expenses and realized and unrealized loss on marketable equity securities.Alnylam recorded total revenues of $500.9 million in the quarter, which missed the Zacks Consensus Estimate of $529 million. In the year-ago quarter, total ...

·2 Alnylam Third Quarter 2024 Financial Results October 31, 2024 1© 2024 Alnylam Pharmaceuticals, Inc. Agenda Welcome • Christine Lindenboom Chief Corporate Communications Officer Overview • Yvonne Greenstreet, MBChB, MBA Chief Executive Officer Commercial Highlights • Tolga Tanguler Chief Commercial Officer Alnylam Pipeline • Pushkal Garg, M.D. Chief Medical Officer Financial Summary and Upcoming Milestones • Jeff Poulton Chief Financial Officer Q&A Session 2 Alnylam Forward Looking Statements This present ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Christine Lindenboom - Chief Corporate Communications Officer Yvonne Greenstreet - Chief Executive Officer Tolga Tanguler - Chief Commercial Officer Pushkal Garg - Chief Medical Officer Jeff Poulton - Chief Financial Officer Conference Call Participants Ellie Merle - UBS Gena Wang - Barclays David Lebowitz - Citi Paul Matteis - Stifel Ritu Baral - TD Cowen Jessica Fye - JPMorgan Gary ...

Alnylam Pharmaceuticals (ALNY) reported $500.92 million in revenue for the quarter ended September 2024, representing a year-over-year decline of 33.3%. EPS of -$0.50 for the same period compares to $1.15 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $529.34 million, representing a surprise of -5.37%. The company has not delivered EPS surprise, with the consensus EPS estimate being -$0.50.While investors closely watch year-over-year changes in headline numbers -- revenue and ea ...

Alnylam Pharmaceuticals (ALNY) came out with a quarterly loss of $0.50 per share in line with the Zacks Consensus Estimate. This compares to earnings of $1.15 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this RNA interference drug developer would post a loss of $0.74 per share when it actually produced earnings of $0.56, delivering a surprise of 175.68%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.A ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________ FORM 10-Q ____________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, $0.01 par value per share ALNY The Nasdaq Stock Market LLC For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 O ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades. Eve ...